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Previewsmicroenvironment or lack of immune sys-
tem that are not equivalent to those
encountered by leukemia cells in the
patient. The authors’ results highlight
the clonal and functional diversity of
LSCs and suggest that future studies
should include an integration of genetic
and functional data as part of their
characterization.
The authors correlated the presence
of specific subclones marked by their
respective mutational spectra with func-
tional readouts, but the mutations that
mechanistically account for the observed
functional differences are unknown. It
will be important to define the genetic
(or epigenetic) determinants that underlie
the observed biology, particularly the
genes or pathways that may promote
engraftment in various immune-compro-
mised mouse models and relapse in
patients.
Xenograft models also serve an instru-
mental role in the preclinical stages of
cancer therapeutics development.
Indeed, almost every FDA-approved
anticancer drug in the modern era has
been tested in such models. However,
they are known to have limitations for
predicting clinical responses in solidtumors (Sharpless and Depinho, 2006),
and the results of Klco et al. (2014) under-
score potential constraints of the ap-
proach to evaluate drug efficacy in AML,
although previous studies have demon-
strated their value in predicting early
relapse in ALL (Meyer et al., 2011). Clonal
analysis through whole genome sequenc-
ing provides a powerful approach for
assessing the fidelity of xenografts in
support of ongoing efforts to devise novel
targeted therapeutics directed at the
pathways and mutant factors that sustain
critical functions of founding clones and/
or cancer stem cells.
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In this issue of Cancer Cell, Kool and colleagues reveal clear genetically defined subclasses of the sonic
hedgehog (SHH) subclass of medulloblastoma. This molecular dissection of the SHH subclass is not simply
a cutting-edge advance; the data have profound impact on clinical trial design and decision-making.Twenty years ago, the world health orga-
nization guidelines and revered neuropa-
thologists encouraged us to ‘‘lump’’ any
small round blue cell tumor in the brain
into a single category for the purpose of
clinical trials and therapeutics. The only
way to improve survival in the ‘‘age of
the lumpers’’ was to intensify therapy, sowe collectively brought the kids to the
very edge of life and death. This resulted
in improved survival rates at the expenses
of both short- and long-term toxicity (Ja-
kacki et al., 2012; Packer et al., 2006).
It is now the age of the ‘‘splitters’’. In
the wake of a half dozen outstanding
medulloblastoma genomics papers in2012, Kool et al. (2014, in this issue of
Cancer Cell) now further show us that
there are at least three distinct molecular
subclasses within the sonic hedgehog
(SHH)-driven subclass of medulloblas-
toma. These data create a double-edged
sword, establishing clear responder hy-
potheses while revealing that, as we5, March 17, 2014 ª2014 Elsevier Inc. 267
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Previewsfurther define the molecular drivers for
each patient, we will at some point lose
our gold-standard phase III trials as a
definitive tool because of small patient
numbers.
Among the four molecular subclasses
of medulloblastoma, SHH-driven tumors
represent about 25%–30% of all patients.
SHH pathway drives the majority of me-
dulloblastomas in infants and adults,
whereas tumors with the SHH molecular
signature are uncommon in children be-
tween the ages of 4 and 17.
Therapeutic agents targeting the SHH
pathway were developed following the
observation that cyclopamine derivatives
caused medulloblastoma cell death and
regression in preclinical models (Berman
et al., 2002). Newer-generation drugs
targeting the smoothened protein are
now in clinical trials. They are not ex-
pected to affect disease caused by
SUFU mutations or GLI2- or MYCN-
amplifications. Whereas certain SMO
mutations were previously shown to
reduce affinity for cyclopamine-like SMO
inhibitors, it is not yet clear whether clini-
cally relevant SMO mutations interfere
with the activity of modern antagonists.
This is why precise genomic analyses for
each child are warranted.
In the study published in this issue of
Cancer Cell, nonoverlapping mutations
in known SHH pathway genes occurred
in 87% of the 133 cases analyzed. This in-
cludes mutations in SHH, SMO, PTCH1,
or SUFO as well as TP53 mutations with
concordant GLI2 or MYCN amplification
and occurred in about half of the remain-
ing cases (Figure 3 of Kool et al., 2014).
The results of the current study (stratified
by age) and my perspective on therapeu-
tic opportunities are highlighted below.
Infants (0–4 years): PTCH1 and SUFU
mutations each drive approximately one-
third of infant medulloblastomas. A small
fraction of the remainder are driven
by SMO or SHH mutations or MYCN
amplification. TP53 mutations are absent
in this age group. Infants respond excep-
tionally well to surgery and traditional
chemotherapy, although toxicity is a
major problem (Geyer et al., 2005). The
likelihood of testing SMO inhibitors in in-
fants with recurrent SHH-driven medullo-
blastoma is vanishingly small, because
these tumors are rare and few children
relapse. Were it not for concerns about
SMO inhibitors interfering with cerebellar268 Cancer Cell 25, March 17, 2014 ª2014 Eor bone growth plate development, it
would be appealing to consider whether
newly-diagnosed infants with complete
surgical resection and PTCH1 mutations
could postpone or avoid chemotherapy
if treated with a SMO inhibitor. As SHH-
driven cerebellar granule cell proliferation
is largely complete by six months of age,
the older children in this group could be
candidates for SMO inhibitors if current
clinical trials reveal the absence of bone
growth toxicity.
Children (4–17 years): nearly half of the
patients in this age range have a mutation
in PTCH1 as an apparent driver. Whether
SMO antagonists could replace selected
more toxic chemotherapy agents in
newly-diagnosed patients would be a
very interesting question to address in a
randomized clinical trial. Of the remaining
patients, most have a TP53 mutation and
amplification of GLI2 and MYCN. These
events occur in conjunction with or as a
consequence of chromothripsis. These
patients experience the poorest outcome
among SHH-driven tumors (Li et al., 1988;
Zhukova et al., 2013), and most cases are
associated with large cell anaplasia (LCA)
pathology. Because of the poor outcome
of LCA patients, the Children’s Oncology
Group now treats children with LCA on
high-risk protocols (Gajjar et al., 2013).
This involves doubling/nearly doubling
the amount of craniospinal irradiation. It
is possible, but far from certain, that
increased radiation will help these pa-
tients survive. But if so, the cost may be
second malignancies as patients with
germline TP53mutation (Li Fraumeni syn-
drome) are at increased risk of second
malignancy (Li et al., 1988).
Adults (over 17 years): over half appear
to be driven by PTCH1 mutations,
whereas most remaining cases seem to
be driven by SMO mutations. Because
of this, Kool et al. (2014) suggest that
82% of adult cases are potentially
responsive to SMO antagonists. This
may be an overestimate, because certain
SMO mutations render certain SMO
antagonists relatively ineffective. The au-
thors make a compelling case for adding
a PI3K/AKT inhibitor to SMO antagonists
in cases where immunohistochemistry
reveals elevated p-AKT or p-S6. In the
absence of p-AKT or p-S6 activation,
nearly 100% of adult medulloblastoma
patients (n = 41) were alive following
standard therapy, whereas survival waslsevier Inc.quite poor among those with elevated
p-AKT or p-S6. The number of younger
patients with elevated p-AKT or p-S6 is
too small to draw conclusions.
Nearly half of the children with malig-
nant brain cancer will die from their
disease. Of those who survive, only one-
fourth will be able to participate in a
long-term relationship or job as adults
because of the neurotoxicity of craniospi-
nal irradiation and chemotherapy. There
is room to be bold in our research and
clinical trial design. Might we find ways
to eliminate radiotherapy and alkylating
chemotherapy altogether for the Li Frau-
meni syndrome patients with germline
TP53 mutations that are at very high risk
for second malignancy? Might we treat
adult patients with both a SMO inhibitor
and a PI3K/AKT inhibitor if they have
SHH-driven medulloblastomas with ele-
vated p-AKT or p-S6? Why not do this at
the time of initial presentation rather than
waiting for recurrence?
Because clinical trials will necessarily
be much smaller than those in the past,
it will be necessary to find agents with
profound effects on the disease in order
to have sufficient statistical power. Paying
close attention to basic pharmacological
properties (e.g., crossing the blood brain
barrier) is critical. Reconsidering trials
in which targeted therapies are used for
cytoreduction following biopsy and prior
to surgery might be indicated for some
groups of patients to reduce the incidence
of surgery-induced cerebellar autism
(a.k.a. posterior fossa syndrome), a brutal
reminder of our current somewhat heavy-
handed approaches. Such ‘‘therapeutic
window’’ trials would also offer a sense
of drug activity in newly-diagnosed pa-
tients using quantitative response criteria.
Patients represented in this study are
the poster children for asking the FDA
to relax barriers to use genomic data to
guide therapeutic decisions in those with
rare diseases, particularly for clinical trials
conducted by cooperative groups. Pedi-
atric neuro-oncologists work together as
a global community to help our patients
(Gottardo et al., 2014). The very fact that
Kool et al. (2014) collected 133 cases of
this rare cancer speaks to our collabora-
tive nature, and many other rare-disease
groups are similarly collaborative and
committed to making thoughtful deci-
sions. Caring for children with brain can-
cer is difficult enough without having
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Previewsto fight to use the knowledge that we have
in hand, such as the elegant work by Kool
et al. (2014).
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A PI3Kd-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent
B cell non-Hodgkin’s lymphomas. In these malignancies, the PI3K pathway is not mutationally activated
as inmany other cancers, but it is important formediating supportive cues from the cancermicroenvironment
and the B cell antigen receptor.Major cancer drug development efforts
currently focus on targeting PI3K
pathway components based on the over-
whelming genetic evidence in support of
a role for this pathway in malignancy
(Fruman and Rommel, 2014). The PI3K
pathway has multiple nodes and is medi-
ated by eight distinct PI3K catalytic
subunits, among which the p110 sub-
units (p110a, b, g, and d) transduce
signals downstream of tyrosine kinases,
G protein-coupled receptors, Ras, and
other small GTPases. Whereas p110a
and p110b show broad tissue dis-
tribution, p110g and p110d are highly
expressed in leukocytes and control
immune responses. PIK3CA, which
encodes p110a, is frequently mutated
and activated in solid tumors, but not
in hematological malignancies. Constitu-
tively activating p110d mutations have
recently been found in a human primary
immunodeficiency disorder without
apparently predisposing to cancer (Fru-man and Rommel, 2014). Other PI3K cat-
alytic subunits have not been found to be
mutated in disease.
Two recent studies report impressive
clinical activity of idelalisib, an oral ATP-
competitive and reversible p110d inhi-
bitor, in relapsed chronic lymphocytic
leukemia (CLL) and indolent non-Hodg-
kin’s lymphomas (iNHLs). All patients
were heavily pretreated and/or not suffi-
ciently fit to undergo standard cytotoxic
chemotherapy. Idelalisib was tested in
combination with rituximab in CLL (Fur-
man et al., 2014) and as a single agent in
iNHL (Gopal et al., 2014). Rituximab is
currently commonly used, although not
approved, as a single agent for treating
relapsed CLL.
NHLs are a heterogeneous group of
lymphomas that arise primarily in the
lymph nodes, and CLL is usually an indo-
lent tumor with accumulation of malig-
nant B cells in lymphatic tissues, bone
marrow, and blood. The course of thesediseases is highly variable, with some
patients never needing treatment. For
those who do, the standard approach is
chemotherapy, which can lead to signifi-
cant toxicities and immunosuppression,
and most patients will relapse. Recent
years have witnessed the development
of more targeted therapies for hemato-
logical malignancies, in particular, small
molecule inhibitors of kinases that
mediate intracellular signal transduction
in lymphocytes, such as Syk and Btk.
Such agents would be expected to be
more tumor selective and better toler-
ated. The rationale for targeting p110d
in B cell malignancy is its key role
in signal transduction downstream of
various B cell receptors, including the
B cell antigen receptor (BCR), cytokine/
chemokine receptors, and adhesion
molecules (Figure 1), contributing to the
regulation of proliferation, differentiation,
migration, and survival (Fruman and
Rommel, 2011).5, March 17, 2014 ª2014 Elsevier Inc. 269
